Comparison Overview

Johnson & Johnson Innovative Medicine

VS

Parexel

Johnson & Johnson Innovative Medicine

None
Last Update: 2025-12-01

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 17,292
Subsidiaries: 10
12-month incidents
0
Known data breaches
0
Attack type number
0

Parexel

541 Church at North Hills St, 1000, Raleigh, North Carolina, US, 27609
Last Update: 2025-12-01
Between 750 and 799

Parexel is among the world’s largest clinical research organizations (CROs), providing the full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster. Leveraging the breadth of our clinical, regulatory and therapeutic expertise, our team of more than 21,000 global professionals collaborates with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind, increasing access and participation to make clinical research a care option for anyone, anywhere. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas, while our innovation ecosystem offers the best solutions to make every phase of the clinical trial process more efficient. With the people, insight and focus on operational excellence, we work every day to treat patients with dignity and continuously learn from their experiences, so every trial makes a difference. For more information, visit parexel.com. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove any comments that do not adhere to our guidelines as well as report users who violate the rules of our page.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 20,504
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/jnjinnovativemedicine.jpeg
Johnson & Johnson Innovative Medicine
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/parexel.jpeg
Parexel
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Johnson & Johnson Innovative Medicine
100%
Compliance Rate
0/4 Standards Verified
Parexel
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Johnson & Johnson Innovative Medicine in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Parexel in 2025.

Incident History — Johnson & Johnson Innovative Medicine (X = Date, Y = Severity)

Johnson & Johnson Innovative Medicine cyber incidents detection timeline including parent company and subsidiaries

Incident History — Parexel (X = Date, Y = Severity)

Parexel cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/jnjinnovativemedicine.jpeg
Johnson & Johnson Innovative Medicine
Incidents

No Incident

https://images.rankiteo.com/companyimages/parexel.jpeg
Parexel
Incidents

No Incident

FAQ

Johnson & Johnson Innovative Medicine company demonstrates a stronger AI Cybersecurity Score compared to Parexel company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Parexel company has disclosed a higher number of cyber incidents compared to Johnson & Johnson Innovative Medicine company.

In the current year, Parexel company and Johnson & Johnson Innovative Medicine company have not reported any cyber incidents.

Neither Parexel company nor Johnson & Johnson Innovative Medicine company has reported experiencing a ransomware attack publicly.

Neither Parexel company nor Johnson & Johnson Innovative Medicine company has reported experiencing a data breach publicly.

Neither Parexel company nor Johnson & Johnson Innovative Medicine company has reported experiencing targeted cyberattacks publicly.

Neither Johnson & Johnson Innovative Medicine company nor Parexel company has reported experiencing or disclosing vulnerabilities publicly.

Neither Johnson & Johnson Innovative Medicine nor Parexel holds any compliance certifications.

Neither company holds any compliance certifications.

Johnson & Johnson Innovative Medicine company has more subsidiaries worldwide compared to Parexel company.

Parexel company employs more people globally than Johnson & Johnson Innovative Medicine company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Johnson & Johnson Innovative Medicine nor Parexel holds SOC 2 Type 1 certification.

Neither Johnson & Johnson Innovative Medicine nor Parexel holds SOC 2 Type 2 certification.

Neither Johnson & Johnson Innovative Medicine nor Parexel holds ISO 27001 certification.

Neither Johnson & Johnson Innovative Medicine nor Parexel holds PCI DSS certification.

Neither Johnson & Johnson Innovative Medicine nor Parexel holds HIPAA certification.

Neither Johnson & Johnson Innovative Medicine nor Parexel holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

Sigstore Timestamp Authority is a service for issuing RFC 3161 timestamps. Prior to 2.0.3, Function api.ParseJSONRequest currently splits (via a call to strings.Split) an optionally-provided OID (which is untrusted data) on periods. Similarly, function api.getContentType splits the Content-Type header (which is also untrusted data) on an application string. As a result, in the face of a malicious request with either an excessively long OID in the payload containing many period characters or a malformed Content-Type header, a call to api.ParseJSONRequest or api.getContentType incurs allocations of O(n) bytes (where n stands for the length of the function's argument). This vulnerability is fixed in 2.0.3.

Risk Information
cvss3
Base: 7.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H
Description

Monkeytype is a minimalistic and customizable typing test. In 25.49.0 and earlier, there is improper handling of user input which allows an attacker to execute malicious javascript on anyone viewing a malicious quote submission. quote.text and quote.source are user input, and they're inserted straight into the DOM. If they contain HTML tags, they will be rendered (after some escaping using quotes and textarea tags).

Risk Information
cvss4
Base: 7.1
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:H/VI:L/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

SysReptor is a fully customizable pentest reporting platform. Prior to 2025.102, there is a Stored Cross-Site Scripting (XSS) vulnerability allows authenticated users to execute malicious JavaScript in the context of other logged-in users by uploading malicious JavaScript files in the web UI. This vulnerability is fixed in 2025.102.

Risk Information
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:U/C:H/I:H/A:N
Description

Taiko Alethia is an Ethereum-equivalent, permissionless, based rollup designed to scale Ethereum without compromising its fundamental properties. In 2.3.1 and earlier, TaikoInbox._verifyBatches (packages/protocol/contracts/layer1/based/TaikoInbox.sol:627-678) advanced the local tid to whatever transition matched the current blockHash before knowing whether that batch would actually be verified. When the loop later broke (e.g., cooldown window not yet passed or transition invalidated), the function still wrote that newer tid into batches[lastVerifiedBatchId].verifiedTransitionId after decrementing batchId. Result: the last verified batch could end up pointing at a transition index from the next batch (often zeroed), corrupting the verified chain pointer.

Risk Information
cvss4
Base: 8.0
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:N/SC:N/SI:N/SA:N/E:U/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A flaw has been found in youlaitech youlai-mall 1.0.0/2.0.0. Affected is the function getById/updateAddress/deleteAddress of the file /mall-ums/app-api/v1/addresses/. Executing manipulation can lead to improper control of dynamically-identified variables. The attack can be executed remotely. The exploit has been published and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

Risk Information
cvss2
Base: 6.5
Severity: LOW
AV:N/AC:L/Au:S/C:P/I:P/A:P
cvss3
Base: 6.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X